Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine I
about
Critical Questions about PARADIGM-HF and the FutureAngiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartanClinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failureCardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fractionNeprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chancesSpotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to dateAngiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyondDual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.The effect of surgical and non-surgical weight loss on N-terminal pro-B-type natriuretic peptide and its relation to obstructive sleep apnea and pulmonary function.PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure TrialCombined Angiotensin Receptor Antagonism and Neprilysin Inhibition.Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved.Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.Geographic variations in the PARADIGM-HF heart failure trial.Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.Novel approaches for treating hypertensionNatriuretic peptides in cardiovascular diseases: current use and perspectivesNovel drug targets in clinical development for heart failure.Novel drug mechanisms in development for heart failure.Newest additions to heart failure treatment.Neprilysin inhibition in chronic kidney diseaseTime and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?New medical therapies for heart failure.A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.Sacubitril/valsartan (LCZ696) for the treatment of heart failure.New Targets in the Drug Treatment of Heart Failure.Patient Selection for Long-Term Mechanical Circulatory Support: Is It Ever too Early for the NYHA Class III Patient?Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits.
P2860
Q26741029-2D65F0DC-FBA0-4680-A067-DA2725662798Q26741084-9FB4DBF0-24AD-4574-8487-26EB72EF17A1Q26747165-6B372208-AC7F-4994-838C-1F5A58B347EDQ26796378-25B4B6A5-9C9B-4E32-8FE8-6A238F592058Q26853363-F29D5F20-6285-4035-9B9F-0132E565BCB8Q27027707-DFCFF946-697D-4C67-8713-3EC7E3C33AAAQ28070064-4F6CABD3-BA8C-456E-ACB2-0C964DF5DCC4Q28088583-AB14E505-06FB-42F9-8A9A-547A30E353C4Q34485114-89FA1851-17AC-49A4-BA7F-03E0522DF4DCQ34495751-AE1AA069-913F-401F-9359-4AAD6F120292Q35035016-4329E83C-63EB-4F56-A35A-FB588AA08F1AQ35164124-3BBE9C59-6AC8-42C6-8DB2-80D0555F6AFCQ36128797-A69A13EA-6E7E-49A6-9620-71F1F778FAD9Q36130409-6016CB87-3500-417A-B408-82367B1E82B8Q36162163-41684C1D-6BC7-40BB-8801-4F50BD458F8AQ36477865-7C1C3081-341F-4CC3-946F-141D6B3F4B25Q36709153-23D49F8B-42EA-46AB-A856-E5F9C4773FD5Q36770945-CDD75F4D-6149-4E0A-BD3B-FC03795A1461Q37394083-DEF4FF36-C1C1-4909-B613-3DFA55C9371FQ37410283-D2E0047C-0442-4109-BEEE-284FE8C3F717Q37595978-F846E1FB-7EEE-41DD-9AE0-D26B04FFDDB2Q37620461-89FF8BCC-580A-4620-9933-F8C86E61F9DEQ38162429-3AEAF46B-3044-464F-9460-B631CC2A9224Q38202895-0B0102BB-8A16-4749-AB52-47CED2F50F13Q38209074-37326286-C3D9-4A2B-AB54-7F6623D1B332Q38225739-6BE11AF6-B247-4245-A3CD-AA9CA3C7D3BEQ38241522-66DD516B-FCCB-4857-ACB3-8F18440FAD55Q38248810-D9577EE5-2FA1-45BE-9902-E8B55CB90BB7Q38261513-B1B16978-6961-401B-993E-8DD19149AE76Q38416785-135505CC-D2BA-4903-AF07-C3282E41F087Q38594785-AD50AE31-AD9D-4C40-8D69-B66A39CB66B0Q38655266-B4C3B746-A34A-4DD9-98B1-72E04951B755Q38661061-6A0FB1F7-337B-45B1-8C9B-934F089FD0F8Q38667210-2A8800BB-4575-43D3-B7F6-9A7C7BD3608EQ38701412-3D2C05D0-19C0-49FB-9796-88AB6E4318D2Q38731859-FE7BC1DE-8362-4396-AFAD-0F981BB85712Q38751093-E651B3BE-8056-4DEE-8139-6AC30E1F4E4EQ38790076-941E1AD2-FC67-426C-B8B0-6043F47EC8D9Q38857852-13EEDDB2-17F9-4126-AA44-296DF6DA10B3Q38859432-AC6C555E-7D58-4DA1-BA71-2BBCBA53E461
P2860
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine I
description
article
@en
im April 2013 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2013
@uk
name
Dual angiotensin receptor and ...... ARNI with ACEI to Determine I
@en
Dual angiotensin receptor and ...... ARNI with ACEI to Determine I
@nl
type
label
Dual angiotensin receptor and ...... ARNI with ACEI to Determine I
@en
Dual angiotensin receptor and ...... ARNI with ACEI to Determine I
@nl
prefLabel
Dual angiotensin receptor and ...... ARNI with ACEI to Determine I
@en
Dual angiotensin receptor and ...... ARNI with ACEI to Determine I
@nl
P2093
P2860
P50
P356
P1476
Dual angiotensin receptor and ...... rt Failure trial (PARADIGM-HF)
@en
P2093
Adel R Rizkala
Akshay S Desai
Jean Rouleau
Karl Swedberg
Martin P Lefkowitz
Milton Packer
Scott D Solomon
Victor C Shi
P2860
P304
P356
10.1093/EURJHF/HFT052
P407
P577
2013-04-05T00:00:00Z